Cargando…
Safe and tolerable one-hour pamidronate infusion for multiple myeloma patients
BACKGROUND: Once a month, patients with multiple myeloma received an infusion of bisphosphonates, principally to reduce osteoclastic bone resorption. Recommended infusion time for pamidronate is 2 hours in the US and 4 hours in Europe because of its potential nephrotoxicity. From 2003, a 90 mg infus...
Autores principales: | Chantzichristos, Dimitrios, Andréasson, Björn, Johansson, Peter |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2643118/ https://www.ncbi.nlm.nih.gov/pubmed/19337444 |
Ejemplares similares
-
Short-term Efficacy of Monthly Pamidronate Infusion in Patients with Osteogenesis Imperfecta
por: Choi, Jin-Ho, et al.
Publicado: (2007) -
Acute Pancreatitis Occurring after Pamidronate Infusions in Two Patients with Spondyloarthritis
por: Toussirot, Éric, et al.
Publicado: (2013) -
Pamidronate infusion improved two cases of intractable seronegative rheumatoid arthritise
por: Salesi, Mansour, et al.
Publicado: (2011) -
Efficacy and safety of intravenous pamidronate infusion for treating osteoporosis in children and adolescents
por: Yoon, Ji-Hee, et al.
Publicado: (2021) -
In Silico Investigations of the Anti-Catabolic Effects of Pamidronate and Denosumab on Multiple Myeloma-Induced Bone Disease
por: Wang, Yan, et al.
Publicado: (2012)